Buy TARO-RAMIPRIL HCTZ 12.5 MG HYDROCHLOROTHIAZIDE

Taro-Ramipril HCTZ 12.5 MG tablets combine ramipril and hydrochlorothiazide for blood pressure management. This medication is used to treat hypertension and may help reduce the risk of heart-related complications.

Strength

12.5 MG

Manufacturer / TM Owner

SUN PHARMA CANADA INC

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Uses / Indications

Taro-Ramipril HCTZ 12.5 MG tablets are commonly used for managing high blood pressure. The combination of ramipril, an ACE inhibitor, and hydrochlorothiazide, a diuretic, works to lower blood pressure by relaxing blood vessels and promoting fluid removal. This medication may be prescribed to individuals who require dual-action therapy for effective blood pressure control.

Side Effects

Common effects of Taro-Ramipril HCTZ 12.5 MG tablets may include dizziness, fatigue, and mild nausea. Some users might experience a dry cough due to the ramipril component. These effects are generally mild and temporary, but persistent or severe symptoms should be discussed with a healthcare provider.

Precautions & Warnings

Taro-Ramipril HCTZ 12.5 MG tablets should be handled with care, especially for individuals with kidney or liver conditions. It is important to stay hydrated and monitor electrolyte levels regularly. Pregnant women should avoid this medication due to potential risks to the fetus.

Avoid Interactions

Taro-Ramipril HCTZ 12.5 MG tablets may interact with certain medications, including nonsteroidal anti-inflammatory drugs (NSAIDs), lithium, and other blood pressure medications. Alcohol consumption should be limited, as it can enhance the blood pressure-lowering effects and increase the risk of dizziness.

References

Frequently Asked Questions

Taro-Ramipril HCTZ 12.5 MG tablets are used to manage high blood pressure by combining the effects of ramipril and hydrochlorothiazide.

Taro-Ramipril HCTZ 12.5 MG tablets are typically taken orally, as directed by a healthcare provider.

Common side effects may include dizziness, fatigue, and mild nausea. A dry cough is also possible due to the ramipril component.

Taro-Ramipril HCTZ 12.5 MG may interact with NSAIDs, lithium, and other blood pressure medications. Always consult a healthcare provider before combining medications.

Taro-Ramipril HCTZ 12.5 MG is generally not recommended during pregnancy due to potential risks to the fetus.

Published by GNH India Pharmaceuticals Limited

Last updated: 18 May 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.